Key goals of EHE include, from 2017 to the end of 2025, reducing new HIV infections and diagnoses by 75%, increasing viral suppression among PWH to 95%, and increasing good or better self-rated health ...

Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for ...

Gilead Sciences, Inc.’s GILD posted 3% year-over-year growth in total revenues for the third quarter of 2025. Total revenues comprise product sales and royalty, contract and other revenues. While ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

In recent years, the story around HIV has shifted dramatically. What was once viewed as a life sentence is now increasingly seen as a manageable condition. Medication is responsible for much of that ...

The United States, whose deep cuts to foreign aid this year under President Trump have severely impacted Africa’s health ...

In people with HIV infection aged 60 years or older, the long-acting cabotegravir and rilpivirine combination maintains high ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

ORLANDO, Fla. — As the Trump administration works to slim down government spending, that includes millions of dollars in funding for HIV medications. LGBT+ Center Orlando was established in 1978. The ...

Some lawmakers and advocates are increasingly uncertain whether critical HIV and AIDS services will survive the federal government’s funding fight. The GOP’s House-passed budget bill seeks to cut over ...

Researchers are increasingly developing antibody therapies to treat infectious diseases. Therapies are being designed to reduce the severity of infections such as bird flu, and cure HIV and other ...